Aeterna Zentaris Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/20/2026)
| Balance Sheet | Total Assets | 29,413,940.35 | ROE | – |
| Balance Sheet | Total Equity | 5,273,125.79 | ROA | – |
| Cashflow | Capital Expenditures | -42,361.66 | P/FCF | – |
| Cashflow | Free Cash Flow | -17,137,000.00 | – | – |
| Cashflow | Operating Cash Flow | -11,629,150.14 | P/CF | – |
| Income | Earnings per Share (diluted) | -3.27 | Div. Yield | – |
| Income | Net Income | -14,216,303.21 | P/E | – |
| Income | Shares Outstanding | 3,183,330.00 | P/B | – |
| Income | Total Revenue | 10,290,967.51 | P/S | – |
Ratios calculated on: –
Company Description
Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.aezsinc.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more